Factors Associated With and Predictive of Persistence of Donor-Specific Antibody After Treatment With Plasmapheresis and Intravenous Immunoglobulin
- 1 April 2005
- journal article
- Published by Elsevier BV in Human Immunology
- Vol. 66 (4), 364-370
- https://doi.org/10.1016/j.humimm.2005.01.032
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Persistence of Low Levels of Alloantibody after Desensitization in Crossmatch-Positive Living-Donor Kidney TransplantationTransplantation, 2004
- Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patientsTransplantation, 2003
- Accurate, rapid charaterization of HLA-specific antibody using luminex technologyHuman Immunology, 2003
- Antibody screening via luminex LABScreenHuman Immunology, 2002
- Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-matchTransplantation Proceedings, 2002
- A comparison of enzyme-linked immunoabsorbent assays and flow cytometry techniques for the detection of HLA specific antibodiesHuman Immunology, 2001
- PLASMAPHERESIS AND INTRAVENOUS IMMUNE GLOBULIN PROVIDES EFFECTIVE RESCUE THERAPY FOR REFRACTORY HUMORAL REJECTION AND ALLOWS KIDNEYS TO BE SUCCESSFULLY TRANSPLANTED INTO CROSS-MATCH-POSITIVE RECIPIENTSTransplantation, 2000
- INTRAVENOUS IMMUNOGLOBULIN SUPPRESSION OF HLA ALLOANTIBODY IN HIGHLY SENSITIZED TRANSPLANT CANDIDATES AND TRANSPLANTATION WITH A HISTOINCOMPATIBLE ORGANTransplantation, 1994
- The different level of expression of HLA-DRB1 and -DRB3 genes is controlled by conserved isotypic differences in promoter sequenceHuman Immunology, 1993
- Extracorporeal Removal of Anti-HLA Antibodies in Transplant CandidatesAmerican Journal of Kidney Diseases, 1990